Does bacille Calmette-Guerin scar size have implications for protection against tuberculosis or leprosy?

Tubercle and Lung Disease

Volumn 77, Issue 2, 1996, Pages 117-123

  Sterne, J A C ^a,c   Fine, P E M ^a   Ponnighaus J M ^b   Sibanda, F ^b   Munthali, M ^b   Glynn, J R ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b LEPRA   (Malawi)

^c ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TUBERCULIN; BCG VACCINE;

ADOLESCENT; ADULT; AGED; ARTICLE; BCG VACCINATION; CHILD; CLINICAL EXAMINATION; COHORT ANALYSIS; FOLLOW UP; HUMAN; IMMUNITY; INCIDENCE; INFANT; LEPROSY; MAJOR CLINICAL STUDY; MALAWI; POPULATION RESEARCH; RISK; SCAR; SCREENING TEST; TUBERCULOSIS; AGE DISTRIBUTION; MIDDLE AGED; PATHOLOGY; PRESCHOOL CHILD;

ADOLESCENT; ADULT; AGE DISTRIBUTION; BCG VACCINE; CHILD; CHILD, PRESCHOOL; CICATRIX; COHORT STUDIES; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; INFANT; LEPROSY; MALAWI; MIDDLE AGED; TUBERCULOSIS;

EID: 0029666123     PISSN: 09628479     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0962-8479(96)90025-8     Document Type: Article

References (23)

1. Mackaness G B. Delayed hypersensitivity and its significance. In: Chamberlayne E C, ed. Immunization in Tuberculosis. Washington DC: Fogarty International Center Proceedings No. 14, US DHEW, 1972: 69-89.
2. WHO Tuberculosis Research Office. Certain characteristics of BCG-induced tuberculin sensitivity. Bull World Health Organ 1955; 12: 123-141.
3. Bahr G M, Stanford J L, Rook G A W, Rees R J W, Abdelnoor A M, Frayha G J. Two potential improvements to BCG and their effect on skin test reactivity in the Lebanon. Tubercle 1986; 67: 205-218.
4. Comstock G W. Identification of an effective vaccine against tuberculosis. Am Rev Respir Dis 1988; 138: 479-480.
5. D'Arcy Hart P, Sutherland I, Thomas J. The immunity conferred by effective BCG and vole bacillus vaccines, in relation to individual variations in induced tuberculin sensitivity and to technical variations in the vaccines. Tubercle 1967; 48: 201-210.
6. Medical Research Council. BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life. Third report to the Medical Research Committee by their Tuberculosis Vaccines Clinical Trials Committee. Br Med J 1963; 1: 973-978.
7. Fine P E M, Sterne J A C, Ponnighaus J M, Rees R J W. Delayed-type hypersensitivity, mycobacterial vaccines and protective immunity. Lancet 1994; 344: 1245-1249.
8. Gill H K, Mustafa A S, Godal T. Induction of delayed-type hypersensitivity in human volunteers immunized with a candidate leprosy vaccine consisting of killed Mycobacterium leprae. Bull World Health Organ 1986; 64: 121-126.
9. Edwards L B, Palmer C E, Magnus K. BCG Vaccination. Studies by the WHO Tuberculosis Research Office, Copenhagen. Geneva: World Health Organization, 1953;
10. Tala-Heikkila M, Nurmela T, Misljenovic O, Bleiker M A, Tala E. Sensitivity to PPD tuberculin and M. scrofulaceum sensitin in schoolchildren BCG vaccinated at birth. Tubercle Lung Dis 1992; 73: 87-93.
11. Fine P E M, Rodrigues L C. Modern Vaccines: Mycobacterial Diseases. Lancet 1990; 335: 1016-1020.
12. Ponnighaus J M, Fine P E M, Bliss L, Sliney I J, Bradley D J, Rees R J W. The Lepra Evaluation Project (LEP) an epidemiological study of leprosy in Northern Malawi. I: Methods. Lepr Rev 1987; 58: 359-375.
13. Ponnighaus J M, Fine P E M, Maine N, Bliss L, Kalambo M, Ponnighaus I M. The Lepra Evaluation Project (LEP), an epidemiological study of leprosy in northern Malawi. II: Prevalence rates. Lepr Rev 1988; 59: 97-112.
14. Fine P E M, Ponnighaus J M, Maine N. The distribution and implications of BCG scars in northern Malawi. Bull World Health Organ 1989; 67: 35-42.
15. Ponnighaus J M, Fine P E M, Bliss L. Certainty levels in the diagnosis of leprosy. Int J Lepr 1987; 55: 454-462.
16. McDougall A C, Ponnighaus J M, Fine P E M. Histopathological examination of skin biopsies from an epidemiological study of leprosy in Northern Malawi. Int J Lepr 1987; 55: 88-98.
17. Ponnighaus J M, Fine P E M, Bliss L et al. The Karonga Prevention Trial: A leprosy and tuberculosis vaccine trial in Northern Malawi - I: Methods of the vaccination phase. Lepr Rev 1993; 64: 338-356.
18. Ponnighaus J M, Fine P E M, Sterne J A C et al. Incidence rates of leprosy in Karonga District, Northern Malawi: patterns by age, sex, BCG status and classification. Int J Lepr 1994; 62: 10-23.
19. Shaw M A, Turner A C, Blackwell J M, Fine P E M, Ponnighaus J M. Setting up HIV serology for the Karonga leprosy vaccine trial in Malawi. Lepr Rev 1991; 62: 87-104.
20. Ponnighaus J M, Mwanjasi L J, Fine P E M et al. Is HIV infection a risk factor for leprosy? Int J Lepr 1991; 59: 221-228.
21. Ponnighaus J M, Fine P E M, Sterne J A C, et al. Efficacy of BCG vaccine against leprosy and tuberculosis in northern Malawi. Lancet 1992; 339: 636-639.
22. Mitinskaya L A. Problems of the prevention of tuberculosis by BCG vaccination. Bull Int Union Tuberc 1979; 54: 332-333.
23. Chavganc J, Hanak R, Ten Dam H G. Epidemiological significance of the local reaction to direct BCG vaccination. Bull World Health Organ 1969; 41: 45-62.